Dr Kantharaj Ethirajulu
currently works at D3, A*STAR, Singapore as Head of Technical, R & D. He is a professional drug discovery & development leader with 20 years of experience in DMPK, CMC and Toxicology and early drug development across therapy areas in both small biotech and large pharmaceutical setting. In D3, he is responsible for all the preclinical development activities starting from preclinical development candidate to IND submissions.
Before joining D3, Dr Ethirajulu headed S*BIO's preclinical development for 7 years. He was involved in the preclinical development of several NMEs leading to successful INDs in USA and regulatory submissions in Singapore and Australia enabling start of clinical studies. He also strategised successful regulatory meetings with both US (FDA) and EU (EMA) for seeking agreements on the non-clinical development plans and strategy from pre-IND stages to advanced clinical development stages. He played a key role in the preclinical development of Pacritinib (SB1518, currently in phase 3 clinical trials), SB1578 (in phase 2) and Pracinostat (HDAC inhibitor in phase 2) currently in advanced stages of clinical development. Previously, Dr Ethirajulu has worked with Johnson & Johnson Pharmaceutical Research and Development as team leader, ADME/Tox department and AstraZeneca R&D as Head of DMPK and Bioanalytical Chemistry.